Astrana Health (NASDAQ:ASTH) Reaches New 1-Year Low After Analyst Downgrade

Astrana Health, Inc. (NASDAQ:ASTH - Get Free Report)'s stock price hit a new 52-week low during trading on Monday after Truist Financial lowered their price target on the stock from $59.00 to $50.00. Truist Financial currently has a buy rating on the stock. Astrana Health traded as low as $29.08 and last traded at $29.42, with a volume of 13470 shares trading hands. The stock had previously closed at $29.48.

ASTH has been the topic of a number of other research reports. Macquarie upgraded shares of Astrana Health to a "hold" rating in a research note on Monday, December 16th. TD Cowen initiated coverage on Astrana Health in a research note on Monday, October 14th. They set a "buy" rating and a $66.00 price objective on the stock. Robert W. Baird lifted their target price on Astrana Health from $67.00 to $86.00 and gave the stock an "outperform" rating in a research report on Wednesday, November 13th. BTIG Research upped their price target on Astrana Health from $60.00 to $70.00 and gave the company a "buy" rating in a research report on Thursday, October 3rd. Finally, KeyCorp assumed coverage on Astrana Health in a research note on Friday, October 11th. They set a "sector weight" rating on the stock. Two analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Astrana Health has an average rating of "Moderate Buy" and an average price target of $63.67.

Institutional Trading of Astrana Health

A number of large investors have recently modified their holdings of ASTH. Principal Financial Group Inc. acquired a new stake in Astrana Health in the third quarter worth about $13,383,000. Franklin Resources Inc. bought a new stake in shares of Astrana Health during the 3rd quarter worth about $1,187,000. Hohimer Wealth Management LLC acquired a new stake in shares of Astrana Health in the 3rd quarter worth approximately $312,000. Geode Capital Management LLC acquired a new position in shares of Astrana Health during the third quarter valued at approximately $58,995,000. Finally, Barclays PLC acquired a new position in shares of Astrana Health during the third quarter valued at approximately $4,457,000. Institutional investors and hedge funds own 52.77% of the company's stock.

Astrana Health Price Performance

The business has a 50-day simple moving average of $39.55 and a two-hundred day simple moving average of $47.05. The company has a quick ratio of 1.91, a current ratio of 1.91 and a debt-to-equity ratio of 0.60. The stock has a market capitalization of $1.70 billion, a price-to-earnings ratio of 23.29, a P/E/G ratio of 1.80 and a beta of 1.20.

Astrana Health (NASDAQ:ASTH - Get Free Report) last announced its quarterly earnings data on Thursday, November 7th. The company reported $0.33 earnings per share for the quarter, meeting the consensus estimate of $0.33. The business had revenue of $478.71 million during the quarter, compared to analyst estimates of $462.01 million. Astrana Health had a return on equity of 9.37% and a net margin of 3.63%. During the same quarter in the prior year, the firm posted $0.47 earnings per share. As a group, research analysts predict that Astrana Health, Inc. will post 1.16 earnings per share for the current fiscal year.

About Astrana Health

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.